These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33477033)

  • 1. Down regulation of U2AF1 promotes ARV7 splicing and prostate cancer progression.
    Cao H; Wang D; Gao R; Chen L; Feng Y
    Biochem Biophys Res Commun; 2021 Feb; 541():56-62. PubMed ID: 33477033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients.
    Sekino Y; Oue N; Mukai S; Shigematsu Y; Goto K; Sakamoto N; Sentani K; Hayashi T; Teishima J; Matsubara A; Yasui W
    Prostate; 2019 Feb; 79(2):234-242. PubMed ID: 30324761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
    Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2.
    Feng S; Tang Q; Sun M; Chun JY; Evans CP; Gao AC
    Mol Cancer Ther; 2009 Mar; 8(3):665-71. PubMed ID: 19240160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.
    Yang Y; Jia D; Kim H; Abd Elmageed ZY; Datta A; Davis R; Srivastav S; Moroz K; Crawford BE; Moparty K; Thomas R; Hudson RS; Ambs S; Abdel-Mageed AB
    Clin Cancer Res; 2016 Apr; 22(7):1744-56. PubMed ID: 26553749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiandrogen bicalutamide activates the androgen receptor (AR) with a mutation in codon 741 through the mitogen activated protein kinase (MARK) pathway in human prostate cancer PC3 cells.
    Terakawa T; Miyake H; Kumano M; Sakai I; Fujisawa M
    Oncol Rep; 2010 Nov; 24(5):1395-9. PubMed ID: 20878136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of curcumin and bicalutamide enhanced the growth inhibition of androgen-independent prostate cancer cells through SAPK/JNK and MEK/ERK1/2-mediated targeting NF-κB/p65 and MUC1-C.
    Li J; Xiang S; Zhang Q; Wu J; Tang Q; Zhou J; Yang L; Chen Z; Hann SS
    J Exp Clin Cancer Res; 2015 May; 34(1):46. PubMed ID: 25971429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
    Marín-Aguilera M; Jiménez N; Reig Ò; Montalbo R; Verma AK; Castellano G; Mengual L; Victoria I; Pereira MV; Milà-Guasch M; García-Recio S; Benítez-Ribas D; Cabezón R; González A; Juan M; Prat A; Mellado B
    Cells; 2020 Jan; 9(1):. PubMed ID: 31947623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-LAK cell-originated protein kinase (TOPK) enhances androgen receptor splice variant (ARv7) and drives androgen-independent growth in prostate cancer.
    Alhawas L; Amin KS; Salla B; Banerjee PP
    Carcinogenesis; 2021 Apr; 42(3):423-435. PubMed ID: 33185682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.
    Takeda K; Hara N; Nishiyama T; Tasaki M; Ishizaki F; Tomita Y
    BMC Cancer; 2016 May; 16():332. PubMed ID: 27225190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
    Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
    Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.
    Li H; Mohamed AA; Sharad S; Umeda E; Song Y; Young D; Petrovics G; McLeod DG; Sesterhenn IA; Sreenath T; Dobi A; Srivastava S
    Oncotarget; 2015 Jun; 6(17):15137-49. PubMed ID: 25883222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
    Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
    Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.